WallStreetZenWallStreetZen

NASDAQ: ICCC
Immucell Revenue

OverviewEarningsRevenue
DividendOwnership
Immucell revenue was $26.49M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $7.8M, up 28.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ICCC annual revenue was $26.5M, with 51.6% growth year-over-year.

ICCC past revenue growth

How has ICCC's revenue growth performed historically?

Company
51.64%
Industry
437.31%
Market
20.27%
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ICCC's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ICCC revenue history

Current Revenue
$26.5M
Current Earnings
-$2.2M
Current Profit Margin
-8.1%

Be the first to know when ICCC announces revenue.

ICCC Revenue History By Year

ICCC Yearly RevenueICCC RevenueICCC ChangeICCC Revenue Growth
2024-12-31$26.49M$9.02M+51.64%
2023-12-31$17.47M-$1.10M-5.90%
2022-12-31$18.57M-$675.01k-3.51%
2021-12-31$19.24M$3.90M+25.43%
2020-12-31$15.34M$1.62M+11.80%
2019-12-31$13.72M$2.74M+24.91%
2018-12-31$10.99M$555.21k+5.32%
2017-12-31$10.43M$887.13k+9.30%
2016-12-31$9.54M-$684.73k-6.69%
2015-12-31$10.23M$2.63M+34.64%
2014-12-31$7.60M$1.59M+26.46%
2013-12-31$6.01M$617.24k+11.45%
2012-12-31$5.39M$278.79k+5.45%
2011-12-31$5.11M$724.95k+16.53%
2010-12-31$4.39M-$119.56k-2.65%
2009-12-31$4.51M-$122.55k-2.65%
2008-12-31$4.63M-$1.44M-23.74%
2007-12-31$6.07M$1.27M+26.41%
2006-12-31$4.80M-$181.87k-3.65%
2005-12-31$4.98M$1.29M+34.82%
2004-12-31$3.70M$338.94k+10.10%
2003-12-31$3.36M-$2.83M-45.72%
2002-12-31$6.18M-$492.06k-7.37%
2001-12-31$6.68M$1.04M+18.47%
2000-12-31$5.64M$726.74k+14.80%
1999-12-31$4.91M$427.38k+9.54%
1998-12-31$4.48M-$74.81k-1.64%
1997-12-31$4.56M$116.49k+2.62%
1996-12-31$4.44M-$497.34k-10.07%
1995-12-31$4.94M$498.78k+11.24%
1994-12-31$4.44MN/AN/A

1 of 3

Immucell Revenue FAQ

What was ICCC's revenue last quarter?

On Invalid Date, Immucell (NASDAQ: ICCC) reported Q4 2024 revenue of $7.75 million up 52.1% year over year. In the same quarter last year, Immucell's revenue was $5.10 million.

What was Immucell's revenue in 2024?

Immucell's annual revenue for the twelve months ending Dec 31, 2024 was $26.49 million, a 51.64% increase year over year.

How much does Immucell make in a day?

Based on Immucell annual revenue for the past five years, ICCC makes an average of $53,215.33 per day.

What was Immucell's annual revenue growth in the past year?

As of Q2 2025, Immucell's revenue has grown 51.64% year over year. This is 385.67 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Immucell's revenue in the past year totaled $26.49 million.

How much does Immucell make in a year?

Immucell's revenue by year for the past five years is:
  • Immucell's revenue for the twelve months ending Dec 31, 2024 was $26.49 million, a 51.64% increase year over year.
  • Immucell's annual revenue for Dec 31, 2023 was $17.47 million, a 5.9% decrease from 2022.
  • Immucell's annual revenue for 2022 was $18.57 million, a 3.51% decrease from 2021.
  • Immucell's annual revenue for 2021 was $19.24 million, a 25.43% increase from 2020.
  • Immucell's annual revenue for 2020 was $15.34 million, a 11.8% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.